Viewing Study NCT05785767


Ignite Creation Date: 2025-12-25 @ 12:43 AM
Ignite Modification Date: 2026-01-22 @ 12:02 PM
Study NCT ID: NCT05785767
Status: RECRUITING
Last Update Posted: 2025-11-21
First Post: 2023-03-14
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)
Sponsor: Regeneron Pharmaceuticals
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module